MX2015009633A - Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. - Google Patents
Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona.Info
- Publication number
- MX2015009633A MX2015009633A MX2015009633A MX2015009633A MX2015009633A MX 2015009633 A MX2015009633 A MX 2015009633A MX 2015009633 A MX2015009633 A MX 2015009633A MX 2015009633 A MX2015009633 A MX 2015009633A MX 2015009633 A MX2015009633 A MX 2015009633A
- Authority
- MX
- Mexico
- Prior art keywords
- pla2
- dihydroimidazol
- pyrimidin
- inhibitors
- associated phospholipase
- Prior art date
Links
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 title abstract 3
- 108010024976 Asparaginase Proteins 0.000 title abstract 3
- YHPVIBUEXBEHPV-UHFFFAOYSA-N 2,6-dihydro-1h-pyrimidin-5-one Chemical compound O=C1CNCN=C1 YHPVIBUEXBEHPV-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013070976 | 2013-01-25 | ||
| CN2013001556 | 2013-12-12 | ||
| PCT/EP2014/051286 WO2014114694A1 (en) | 2013-01-25 | 2014-01-23 | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015009633A true MX2015009633A (es) | 2015-11-30 |
Family
ID=50002724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009633A MX2015009633A (es) | 2013-01-25 | 2014-01-23 | Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9708330B2 (enExample) |
| EP (1) | EP2948452B1 (enExample) |
| JP (1) | JP6306053B2 (enExample) |
| KR (1) | KR20150108897A (enExample) |
| CN (1) | CN105008368B (enExample) |
| AU (1) | AU2014209949B2 (enExample) |
| BR (1) | BR112015017759B1 (enExample) |
| CA (1) | CA2899091A1 (enExample) |
| CL (1) | CL2015002060A1 (enExample) |
| CR (1) | CR20150390A (enExample) |
| EA (1) | EA025885B1 (enExample) |
| ES (1) | ES2642762T3 (enExample) |
| HK (1) | HK1216425A1 (enExample) |
| IL (1) | IL240046A0 (enExample) |
| MA (1) | MA38284B1 (enExample) |
| MX (1) | MX2015009633A (enExample) |
| PE (1) | PE20151251A1 (enExample) |
| PH (1) | PH12015501586A1 (enExample) |
| SG (1) | SG11201505520WA (enExample) |
| TW (1) | TW201443054A (enExample) |
| UY (1) | UY35276A (enExample) |
| WO (1) | WO2014114694A1 (enExample) |
| ZA (1) | ZA201505025B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014114694A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
| WO2016012917A1 (en) * | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012916A1 (en) * | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| EP3172211B1 (en) | 2014-07-22 | 2019-07-03 | GlaxoSmithKline Intellectual Property Development Limited | Tricyclic imidazo-pyrimidinone derivatives for the treatment of diseases mediated by lp-pla2 |
| CN104892459A (zh) * | 2015-06-16 | 2015-09-09 | 苏州明锐医药科技有限公司 | 利奥西呱中间体及其制备方法 |
| CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN114805389B (zh) * | 2019-11-09 | 2023-08-29 | 上海赛默罗生物科技有限公司 | 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN111533699B (zh) * | 2020-05-27 | 2023-12-01 | 龙曦宁（上海）医药科技有限公司 | 一种2-（三氟甲基）嘧啶-5-醇的合成方法 |
| CN113861220B (zh) * | 2020-06-30 | 2023-06-16 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN113912622B (zh) | 2020-07-10 | 2023-12-01 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN114057740B (zh) * | 2021-12-15 | 2024-04-02 | 上海赛默罗生物科技有限公司 | 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| JP2025527291A (ja) * | 2022-08-04 | 2025-08-20 | ４ビー テクノロジーズ （ベイジン） カンパニー リミテッド | Ｌｐ－ＰＬＡ２阻害剤としてのジヒドロイミダゾピリミジノン化合物およびその使用 |
| CN118221687B (zh) | 2023-07-17 | 2024-12-31 | 上海枢境生物科技有限公司 | 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用 |
| CN116925023B (zh) * | 2023-07-18 | 2025-11-21 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018035A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| WO1996019451A1 (en) | 1994-12-22 | 1996-06-27 | Smithkline Beecham Plc | Substituted azetidin-2-ones for treatment of atherosclerosis |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| HUP9901153A3 (en) | 1995-07-01 | 1999-11-29 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them |
| WO1997012963A2 (en) | 1995-09-29 | 1997-04-10 | Smithkline Beecham Plc | A paf-acetylhydrolase and use in therapy |
| EP0869943A1 (en) | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
| EP0865429A1 (en) | 1995-12-08 | 1998-09-23 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
| CZ341098A3 (cs) | 1996-04-26 | 1999-03-17 | Smithkline Beecham Plc | Azetidinonové deriváty pro ošetřování aterosklerózy |
| GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| WO1999024420A1 (en) | 1997-11-06 | 1999-05-20 | Smithkline Beecham Plc | Pyrimidinone compounds and pharmaceutical compositions containing them |
| DE69911980T2 (de) | 1998-08-21 | 2004-09-09 | Smithkline Beecham P.L.C., Brentford | Pyrimidinonderivate zur behandlung von atheroscleros |
| GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| DE60042286D1 (de) | 1999-05-01 | 2009-07-09 | Smithkline Beecham Plc | Pyrimidinon Verbindungen |
| GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| JP3757703B2 (ja) | 1999-09-22 | 2006-03-22 | 凸版印刷株式会社 | 再封可能な開口維持部材付パウチ |
| DE60139429D1 (de) | 2000-02-16 | 2009-09-10 | Smithkline Beecham Plc | Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren |
| GB0024807D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0119793D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
| GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127141D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
| GB0127139D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127140D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0208280D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| EP1644353A1 (de) | 2003-07-02 | 2006-04-12 | Bayer HealthCare AG | Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten |
| DE102004061008A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one |
| DE102004061009A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
| US20080090852A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US7705005B2 (en) | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| WO2008048867A2 (en) | 2006-10-13 | 2008-04-24 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| US20080090851A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| US9029383B2 (en) | 2007-05-11 | 2015-05-12 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| JP2011088847A (ja) | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
| EP2619203A4 (en) * | 2010-09-20 | 2014-04-16 | Glaxo Group Ltd | TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF |
| WO2012075917A1 (en) * | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Compounds |
| EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
| EP2739627A4 (en) * | 2011-07-27 | 2015-01-21 | Glaxo Group Ltd | 2,3-DIHYDROIMIDAZO- [1,2-C-] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AS LP-PLA² INHIBITORS |
| WO2014114694A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
-
2014
- 2014-01-23 WO PCT/EP2014/051286 patent/WO2014114694A1/en not_active Ceased
- 2014-01-23 PE PE2015001537A patent/PE20151251A1/es not_active Application Discontinuation
- 2014-01-23 CN CN201480013675.8A patent/CN105008368B/zh not_active Expired - Fee Related
- 2014-01-23 ES ES14701355.1T patent/ES2642762T3/es active Active
- 2014-01-23 EA EA201591379A patent/EA025885B1/ru not_active IP Right Cessation
- 2014-01-23 HK HK16104389.3A patent/HK1216425A1/zh unknown
- 2014-01-23 MA MA38284A patent/MA38284B1/fr unknown
- 2014-01-23 US US14/761,636 patent/US9708330B2/en not_active Expired - Fee Related
- 2014-01-23 TW TW103102388A patent/TW201443054A/zh unknown
- 2014-01-23 BR BR112015017759-0A patent/BR112015017759B1/pt not_active IP Right Cessation
- 2014-01-23 UY UY0001035276A patent/UY35276A/es not_active Application Discontinuation
- 2014-01-23 CA CA2899091A patent/CA2899091A1/en not_active Abandoned
- 2014-01-23 KR KR1020157022396A patent/KR20150108897A/ko not_active Ceased
- 2014-01-23 SG SG11201505520WA patent/SG11201505520WA/en unknown
- 2014-01-23 JP JP2015554138A patent/JP6306053B2/ja not_active Expired - Fee Related
- 2014-01-23 AU AU2014209949A patent/AU2014209949B2/en not_active Ceased
- 2014-01-23 EP EP14701355.1A patent/EP2948452B1/en active Active
- 2014-01-23 MX MX2015009633A patent/MX2015009633A/es unknown
-
2015
- 2015-07-13 ZA ZA2015/05025A patent/ZA201505025B/en unknown
- 2015-07-20 IL IL240046A patent/IL240046A0/en unknown
- 2015-07-20 PH PH12015501586A patent/PH12015501586A1/en unknown
- 2015-07-23 CL CL2015002060A patent/CL2015002060A1/es unknown
- 2015-07-24 CR CR20150390A patent/CR20150390A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2948452A1 (en) | 2015-12-02 |
| CR20150390A (es) | 2015-10-19 |
| CN105008368B (zh) | 2017-02-01 |
| US9708330B2 (en) | 2017-07-18 |
| WO2014114694A1 (en) | 2014-07-31 |
| CA2899091A1 (en) | 2014-07-31 |
| PE20151251A1 (es) | 2015-09-10 |
| PH12015501586A1 (en) | 2015-10-05 |
| IL240046A0 (en) | 2015-08-31 |
| EP2948452B1 (en) | 2017-08-09 |
| CN105008368A (zh) | 2015-10-28 |
| CL2015002060A1 (es) | 2015-11-27 |
| EA201591379A1 (ru) | 2016-01-29 |
| US20150361082A1 (en) | 2015-12-17 |
| ZA201505025B (en) | 2017-08-30 |
| ES2642762T3 (es) | 2017-11-20 |
| HK1216425A1 (zh) | 2016-11-11 |
| SG11201505520WA (en) | 2015-08-28 |
| JP6306053B2 (ja) | 2018-04-04 |
| JP2016505058A (ja) | 2016-02-18 |
| KR20150108897A (ko) | 2015-09-30 |
| AU2014209949B2 (en) | 2016-09-08 |
| EA025885B1 (ru) | 2017-02-28 |
| TW201443054A (zh) | 2014-11-16 |
| UY35276A (es) | 2014-08-29 |
| AU2014209949A1 (en) | 2015-07-30 |
| MA38284B1 (fr) | 2018-05-31 |
| BR112015017759A2 (pt) | 2017-07-11 |
| MA38284A1 (fr) | 2017-12-29 |
| BR112015017759B1 (pt) | 2022-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501586A1 (en) | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors | |
| PH12017501921A1 (en) | Novel compounds | |
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| MX2015005015A (es) | Inhibidores heteroarilo de pde4. | |
| BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| CA2871471C (en) | Dna-pk inhibitors | |
| SG10201909545XA (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| PH12016501307B1 (en) | Compounds | |
| PH12013500299B1 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| UA115677C2 (uk) | ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ | |
| IN2014DN10386A (enExample) | ||
| IN2015DN01156A (enExample) | ||
| IN2014DN07384A (enExample) | ||
| PH12013501089A1 (en) | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 | |
| TN2013000325A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
| EA201891067A1 (ru) | [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| TN2015000328A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| MX2013011421A (es) | Derivados de pirazolo-pirimidina. | |
| UA111520C2 (uk) | [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази | |
| IN2014DN08443A (enExample) | ||
| MX2015005312A (es) | Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12. | |
| NZ728660A (en) | A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor | |
| IN2014DN06536A (enExample) |